Printer Friendly

IMRE CORP. FILLS THREE SENIOR MANAGEMENT POSITIONS

 SEATTLE, Oct. 11 /PRNewswire/ -- IMRE Corp. (NASDAQ: IMRE) announced today that three senior management personnel have joined the company in executive positions. The three officers bring over 40 years of healthcare experience to the company having held management positions with Syntex Laboratories Inc., Baxter International Inc., Fresenius Ltd. and the biotechnology practice of Coopers & Lybrand.
 Duane Morris was hired as vice president of manufacturing. Prior to joining IMRE Corp., Morris was the director of pharmaceutical manufacturing for Syntex Laboratories Inc., where he spent the past 19 years in positions of increasing responsibility. Morris will be in charge of the company's expanded manufacturing operations which received FDA clearance earlier this year.
 John Wynne assumed the position of vice president of marketing and business development. Before relocating to the United States, Wynne was the managing director of the company's wholly owned subsidiary, IMRE Europe Ltd. Wynne has over 14 years of experience in the healthcare industry having held senior management positions in sales, marketing, and business development with Fresenius Ltd. and Baxter International Inc.
 Alex de Soto was appointed vice president and chief financial officer. de Soto, a CPA, came to IMRE from Coopers & Lybrand's high technology practice where he had extensive experience in managing and reviewing financial affairs for public and closely held companies. His experience includes serving multi-national companies for two years in Coopers & Lybrand's London office and involvement in acquisitions and biotechnology public offerings.
 IMRE Corp. is a medical products company that is the leader in the field of immunoadsorption treatments. The company's first product, the PROSORBA(R) column, has been approved by the Food and Drug Administration and is marketed and sold for treatment of immune thrombocytopenic purpura (ITP), an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases and certain cancers.
 -0- 10/11/93
 /CONTACT: Lois Yoshida of IMRE, 206-298-9400/
 (IMRE)


CO: IMRE Corp. ST: Washington IN: MTC SU: PER

RB-JH -- SE005 -- 0544 10/11/93 08:33 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 11, 1993
Words:330
Previous Article:LATTICE TRIPLES ITS HIGH DENSITY PRODUCT LINE; RAISES INDUSTRY'S BAR ON SPEED, DENSITY AND TESTABILITY
Next Article:HARPER GROUP FINISHES FIRST FOR U.S. OLYMPIC COMMITTEE BUSINESS; OPENS EL PASO OFFICE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters